These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 360759)

  • 1. Dopaminergic agonist Ro 8-4650 in Parkinson's disease. I. Patients treated with dopa.
    Birket-Smith E; Bøttcher J; Dupont E; Holm P; Jensen JP; Kristensen O; Køhler O; Mikkelsen B
    Acta Neurol Scand; 1978 Jul; 58(1):74-6. PubMed ID: 360759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopaminergic agonist Ro 8-4650 in Parkinson's disease. II. Patients not treated with dopa.
    Presthus J; Ankerhus J; Burén A; Bøttcher J; Holmsen R; Mikkelsen B; Mikkelsen BO; Nyberg-Hansen R; Riman E; Severin B; Aarli JA
    Acta Neurol Scand; 1978 Jul; 58(1):77-9. PubMed ID: 360760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bromocriptine versus placebo in levodopa treated patients with Parkinson's disease.
    Gron U
    Acta Neurol Scand; 1977 Sep; 56(3):269-73. PubMed ID: 333855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nomifensine in parkinsonism.
    Park DM; Findley LJ; Teychenne PF
    Br J Clin Pharmacol; 1977; 4Suppl 2(Suppl 2):185S-186S. PubMed ID: 334222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The L-dopa sparing effect of G 31,406 in the treatment of parkinson's disease.
    Couto B; Oliveira C; Mattos JP; Freitas MR
    Neurol Neurocir Psiquiatr; 1976; 17(4):285-92. PubMed ID: 798128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bromocryptine in levodopa response-losing parkinsonism. A double blind study.
    Jansen EN
    Eur Neurol; 1978; 17(2):92-9. PubMed ID: 344042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease.
    Agid Y; Pollak P; Bonnet AM; Signoret JL; Lhermitte F
    Lancet; 1979 Mar; 1(8116):570-2. PubMed ID: 85162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nomifensine in Parkinson's disease.
    Bedard P; Parkes JD; Marsden CD
    Br J Clin Pharmacol; 1977; 4Suppl 2(Suppl 2):187S-190S. PubMed ID: 334223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial.
    Presthus J; Berstad J; Lien K
    Acta Neurol Scand; 1987 Sep; 76(3):200-3. PubMed ID: 3120487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromocriptine in the treatment of advanced Parkinsonism.
    Kristensen O; Hansen E
    Acta Neurol Scand; 1977 Sep; 56(3):274-6. PubMed ID: 333856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy of Parkinson's disease.
    Cohen MM; Scheife RT
    Am J Hosp Pharm; 1977 May; 34(5):531-8. PubMed ID: 326045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
    Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.
    Tarsy D; Parkes JD; Marsden CD
    J Neurol Neurosurg Psychiatry; 1975 Apr; 38(4):331-5. PubMed ID: 1095689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Randomized study during a year of early combination of L-dopa/lisuride in Parkinson disease].
    Vermersch P; Fondarai J; Petit H
    Therapie; 1991; 46(6):481-6. PubMed ID: 1819154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine agonist monotherapy in Parkinson's disease.
    Clarke CE; Guttman M
    Lancet; 2002 Nov; 360(9347):1767-9. PubMed ID: 12480442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nomifensine in parkinsonism.
    Teychenne PF; Park DM; Findley LJ; Rose FC; Calne DB
    J Neurol Neurosurg Psychiatry; 1976 Dec; 39(12):1219-21. PubMed ID: 796415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deanol and physostigmine in the treatment of L-dopa-induced dyskinesias.
    Lindeboom SF; Lakke JP
    Acta Neurol Scand; 1978 Aug; 58(2):134-8. PubMed ID: 360761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.